Neuvenge active in refractory HER2+ breast ca

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 9
Volume 16
Issue 9

Lapuleucel-T (Neuvenge, Dendreon Corporation), an autologous active cellular immunotherapy designed to stimulate cellular immune responses against HER2/neu, proved feasible and well tolerated with evidence of anticancer activity in a phase I trial.

SAN FRANCISCO—Lapuleucel-T (Neuvenge, Dendreon Corporation), an autologous active cellular immunotherapy designed to stimulate cellular immune responses against HER2/neu, proved feasible and well tolerated with evidence of anticancer activity in a phase I trial. The study included 19 patients with HER2-overexpressing metastatic breast cancer who had failed standard therapy, including prior chemotherapy and treatment with trastuzumab (Herceptin).

Lead author John W. Park, MD, of the University of California, San Francisco, and his colleagues at UCSF and Dendreon, reported the results in the August 20 issue of the Journal of Clinical Oncology (25:3680-3687, 2007).

"Significant cellular immune responses specific for the immunizing antigen and HER2 sequences were induced after treatment," Dr. Park reported. Evidence of anticancer activity was seen in 22% of patients, including one patient who had a partial response lasting 6 months and three who had stable disease for more than a year without any other cancer therapy other than bisphosphonates. Two additional patients had stable disease for up to 20 weeks.

Related Videos
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Carey Anders, MD, an expert on breast cancer
Related Content